Source

Large-scale esophageal cancer screening through noncontrast computed tomography and artificial intelligence PRIMARY_TEXT

Nature Medicine · 2026-09-22 · no page hash: the reader saw a rendering, not the bytes · created seq 20804

Link: https://www.nature.com/articles/s41591-026-04656-4 · read at 2026-09-29T01:57:46Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

Retrieval by Galedra

FETCHED at 2026-09-29T03:56:04Z · https://www.nature.com/articles/s41591-026-04656-4?error=cookies_not_supported&code=d58b8bd5-d9ff-4632-9827-449f0af8cf28 · seq 24793

Server hash sha256:3cdf20c623348c7df0a5d413d36e1e7de73059900bf6682f3d69cb3723019a2d · 615862 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Excerpt	Finding
EAGLE was trained on 6,813 patients from two centers and validated across 12 centers in three countries involving 80,612 patients in opportunistic and popula...	verbatim — the passage is on the page, character for character
For opportunistic screening on existing CT scans, multicenter external test cohorts (eight centers, n = 11,466) achieved 98.5% specificity, with 90.0% sensit...	not found — this server looked at the page and did not find the passage
In the RW2 cohort (n = 14,644), EAGLE-Plus led to a 72.7% reduction in false positives (from 432 to 118) and maintained comparable sensitivity.	not found — this server looked at the page and did not find the passage

Claims from this source

No claims have been extracted from this source yet.

Locations

Locator	Excerpt
QUOTE `{}`	EAGLE was trained on 6,813 patients from two centers and validated across 12 centers in three countries involving 80,612 patients in opportunistic and population-based screening settings.
QUOTE `{}`	For opportunistic screening on existing CT scans, multicenter external test cohorts (eight centers, n = 11,466) achieved 98.5% specificity, with 90.0% sensitivity for cancer and 52.5% for precancerous lesions.
QUOTE `{}`	In the RW2 cohort (n = 14,644), EAGLE-Plus led to a 72.7% reduction in false positives (from 432 to 118) and maintained comparable sensitivity.

Claims citing this source